Development of a psilocin immunoassay for serum and blood samples
- 131 Downloads
After the immunisation of rabbits with a psilocin-specific immunogen, polyclonal antisera were obtained. With these antisera a competitive, heterogeneous radioimmunoassay for the detection of psilocin was developed. As tracer a derivative of psilocin was synthesised, which contained a tritiated CH3 group. The antisera showed a specific reaction with psilocin. The cross-reactivity of structurally related endogenous substances like serotonin, tryptophan and tyrosine was below 0.01%. Also common drugs of abuse (Δ9-tetrahydrocannabinol, cocaine, morphine, amphetamine) showed negligible cross-reactivity (0.01–2%). Only tricyclic neuroleptics with a (dimethylamino)ethyl side-chain showed some cross-reactivity (20%). Spiked serum and blood samples were analysed with this new immunoassay and the results obtained were compared with the values measured with a validated GC-MS method.
KeywordsPsilocin Radioimmunoassay GC-MS
The authors wish to thank Dr. W. Schneider and the staff from Dade Behring GmbH Marburg who were responsible for the animal experimental section.
- 8.Lindenblatt H, Kramer E, Holzmann-Erens P, Gouzoulis-Mayfrank E, Kovar K-A (1998) Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated online solid-phase extraction. J Chromatogr B Biomed Sci Appl 709:255–263CrossRefPubMedGoogle Scholar
- 11.Kamata T, Nishikawa M, Katagi M, Tsuchihashi H (2003) Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 792:421–427Google Scholar
- 16.Yamada F, Tamura M, Somei M (1998) A facile synthesis of psilocin from indole-3-carbaldehyde. Heterocycles 49:451–457Google Scholar
- 18.Troxler F, Seemann F, Hofmann A (1959) Synthetic indole compounds. II. Psilocybin and psilocin modifications. Helv Chim Acta 42:2073–2103Google Scholar
- 19.U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Medicine CfV (2001) Guidance for industry. Bioanalytical validationGoogle Scholar